FDA Panel Accepts Ad Hoc Analysis To Support Low Dose Of Pasireotide For Cushing’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The Endocrinologic and Metabolic Drugs Advisory Committee Nov. 7 unanimously recommended approval of Novartis’ Signifor for the orphan condition.